CymaBay Announces Positive Top-Line Data from Phase 3 Trial of Seladelpar for Primary Biliary Cholangitis
CymaBay Therapeutics reported positive top-line results from the ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy […]